Biotech Values

[DewDiligence]

Mavyret’s US market share continues growth—week ending 3/2/18 (according to IMS):

• ABBV/ENTA’s NRx share=39.6%, the highest-ever weekly figure.

• ABBV/ENTA’s TRx share=35.1%, also the highest ever.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)

The gap between ABBV/ENTA’s NRx% and TRx% (now only 4.5%) is narrowing insofar as most US Harvoni patients are now being treated for 8 weeks rather than 12 weeks; thus GILD’s advantage vs ABBV/ENTA in average duration of treatment per patient is shrinking.